Idera Pharmaceuticals (IDRA) Stock: Diamond In The Rough Or Lump Of Coal?

As with any clinical-stage biotechnology company, IDRA comes with some risk. First and foremost, when a company is clinical-stage, it means that there are currently no products. So, the company is heavily financially dependent on its supporters, lenders, and shareholders. This will be the case until the company not only achieves regulatory approval, but also achieves successful commercialization of the aforementioned approved product.

With that said, investments in clinical-stage biotechnology companies like IDRA can be overwhelmingly profitable in the long run. However, they are also highly speculative and include a high degree of risk. So, when considering an investment in Idera Pharmaceuticals or any other clinical-phase biotechnology company, please make sure that you consider the risks!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!




Is Now The Time To Get Involved In IDRA?

At the end of the day, only you can answer this question given your unique goals. However, it’s definitely an interesting option. The company has multiple clinical catalysts on the horizons. Also, with a partner like GlaxoSmithKline, there’s definitely some potential here. Nonetheless, it’s important to consider the risks. So, before making an investment, ask yourself 2 questions:

  1. Do you truly believe that IDRA has a strong chance of obtaining regulatory approval?
  2. Are you willing to accept the risks associated with investing in a clinical-phase biotechnology company?

By answering the questions above, you’ll have a good idea of whether or not now is the time for you to consider an investment in IDRA.

Leave a Comment